|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007226,
umls-concept:C0032105,
umls-concept:C0035647,
umls-concept:C0205217,
umls-concept:C0279214,
umls-concept:C0286651,
umls-concept:C0333348,
umls-concept:C0441889,
umls-concept:C0681850,
umls-concept:C1539477,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C1749467,
umls-concept:C1947946,
umls-concept:C2349001,
umls-concept:C2603343,
umls-concept:C2697811,
umls-concept:C2745888
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-12-22
|
|
pubmed:abstractText |
Increasing evidence indicates that the Fas/Fas ligand interaction is involved in atherogenesis. We sought to analyze soluble Fas (sFas) and soluble Fas ligand (sFasL) concentrations in subjects at high cardiovascular risk and their modulation by atorvastatin treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1524-4636
|
|
pubmed:author |
pubmed-author:ACTFAST investigators,
pubmed-author:Blanco-ColioLuis MLM,
pubmed-author:EgidoJesúsJ,
pubmed-author:FarsangCsabaC,
pubmed-author:GawAllanA,
pubmed-author:GensiniGianFrancoG,
pubmed-author:HérnandezGonzaloG,
pubmed-author:LangerAnatolyA,
pubmed-author:LeiterLawrence ALA,
pubmed-author:Martín-VenturaJose LJL,
pubmed-author:MartineauPierreP,
pubmed-author:de TeresaEduardoE
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
168-74
|
|
pubmed:meshHeading |
pubmed-meshheading:17053166-Aged,
pubmed-meshheading:17053166-Anticholesteremic Agents,
pubmed-meshheading:17053166-Antigens, CD95,
pubmed-meshheading:17053166-C-Reactive Protein,
pubmed-meshheading:17053166-Cardiovascular Diseases,
pubmed-meshheading:17053166-Diabetes Mellitus,
pubmed-meshheading:17053166-Dose-Response Relationship, Drug,
pubmed-meshheading:17053166-Fas Ligand Protein,
pubmed-meshheading:17053166-Female,
pubmed-meshheading:17053166-Gene Expression Regulation,
pubmed-meshheading:17053166-Heptanoic Acids,
pubmed-meshheading:17053166-Humans,
pubmed-meshheading:17053166-Male,
pubmed-meshheading:17053166-Metabolic Syndrome X,
pubmed-meshheading:17053166-Middle Aged,
pubmed-meshheading:17053166-Prospective Studies,
pubmed-meshheading:17053166-Pyrroles,
pubmed-meshheading:17053166-Risk Factors
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST.
|
|
pubmed:affiliation |
Vascular Research Laboratory, Fundación Jiménez Díaz, Autonoma University, Avenida Reyes Católicos 2, 28040, Madrid, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
